Research Analysts Issue Forecasts for CORT FY2026 Earnings

Key Points

• Zacks Research has increased its FY2026 earnings per share estimate for Corcept Therapeutics to $1.68 from a previous estimate of $1.65, while the consensus estimate stands at $1.36.
• Corcept's stock performance shows a current price of $67.17, with a market capitalization of $7.12 billion and a price-to-earnings ratio of 57.91.
• Recent trading activity includes insiders selling shares, with an insider decreasing their position by 8.35% after selling shares at around $73.44 each.

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Analysts at Zacks Research lifted their FY2026 EPS estimates for Corcept Therapeutics in a research report issued on Wednesday, July 30th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $1.68 per share for the year, up from their prior estimate of $1.65. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.29 earnings per share for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. The firm had revenue of $194.43 million for the quarter, compared to analyst estimates of $199.40 million. Corcept Therapeutics had a net margin of 18.51% and a return on equity of 20.10%. The business's revenue was up 18.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.32 earnings per share.

Several other analysts have also issued reports on the stock. Piper Sandler dropped their price target on shares of Corcept Therapeutics from $131.00 to $121.00 and set an "overweight" rating on the stock in a research report on Friday. HC Wainwright dropped their price target on shares of Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Truist Financial set a $135.00 price target on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. Canaccord Genuity Group decreased their price objective on shares of Corcept Therapeutics from $142.00 to $137.00 and set a "buy" rating on the stock in a report on Friday. Finally, Wall Street Zen downgraded shares of Corcept Therapeutics from a "buy" rating to a "hold" rating in a report on Wednesday, May 14th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Corcept Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $134.50.

Corcept Therapeutics Stock Up 4.0%

Shares of CORT stock traded up $2.77 during trading on Friday, reaching $71.77. The company's stock had a trading volume of 1,816,053 shares, compared to its average volume of 1,380,373. The business has a fifty day moving average price of $71.62 and a 200-day moving average price of $68.53. The company has a market cap of $7.61 billion, a price-to-earnings ratio of 63.51 and a beta of 0.20. Corcept Therapeutics has a one year low of $32.33 and a one year high of $117.33.

Insider Buying and Selling at Corcept Therapeutics

In related news, CEO Joseph K. Belanoff sold 615 shares of the firm's stock in a transaction that occurred on Thursday, July 17th. The shares were sold at an average price of $73.69, for a total value of $45,319.35. Following the completion of the transaction, the chief executive officer owned 2,901,370 shares in the company, valued at $213,801,955.30. This trade represents a 0.02% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Sean Maduck sold 473 shares of the stock in a transaction that occurred on Friday, July 18th. The shares were sold at an average price of $73.44, for a total transaction of $34,737.12. Following the sale, the insider directly owned 17,705 shares of the company's stock, valued at $1,300,255.20. This represents a 2.60% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 173,038 shares of company stock valued at $13,237,621 over the last three months. 20.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Corcept Therapeutics

Several large investors have recently bought and sold shares of CORT. American Century Companies Inc. raised its stake in shares of Corcept Therapeutics by 1.7% during the 4th quarter. American Century Companies Inc. now owns 98,868 shares of the biotechnology company's stock worth $4,982,000 after purchasing an additional 1,622 shares during the period. LPL Financial LLC raised its stake in shares of Corcept Therapeutics by 47.9% during the 4th quarter. LPL Financial LLC now owns 60,682 shares of the biotechnology company's stock worth $3,058,000 after purchasing an additional 19,650 shares during the period. JPMorgan Chase & Co. raised its stake in shares of Corcept Therapeutics by 2.7% during the 4th quarter. JPMorgan Chase & Co. now owns 259,902 shares of the biotechnology company's stock worth $13,096,000 after purchasing an additional 6,832 shares during the period. Norges Bank purchased a new stake in Corcept Therapeutics in the 4th quarter worth about $42,055,000. Finally, New Age Alpha Advisors LLC purchased a new stake in Corcept Therapeutics in the 4th quarter worth about $177,000. 93.61% of the stock is currently owned by institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.